AdvanSix Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied filing text does not provide standalone fourth-quarter financial results. AdvanSix is a U.S.-based, vertically integrated chemical manufacturer with one reportable segment and five manufacturing sites. Its principal products are Nylon 6, caprolactam, chemical intermediates and ammonium sulfate fertilizer.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Sales | $1,945.6 million | $1,684.6 million |
| Gross margin | 16.2% | 16.3% |
| Net income | $171.9 million | $139.8 million |
| Diluted EPS | $5.92 | $4.81 |
| Adjusted EBITDA (non-GAAP) | $308.5 million | $267.0 million |
| Adjusted EBITDA margin (non-GAAP) | 15.9% | 15.8% |
| Operating cash flow | $273.6 million | $218.8 million |
| Capital expenditures | $89.4 million | $56.8 million |
Sales rose 15.5%, while net income increased about 23%. Cash and cash equivalents were $31.0 million at year-end. Revolver borrowings were $115 million, with approximately $384 million of additional availability under the $500 million facility, maturing in October 2026. The company reported compliance with its debt covenants. Total assets were $1.50 billion and total liabilities were $757.2 million. The filing does not provide a standalone current ratio.
Material changes versus 2021
- Higher market-based pricing and formula pass-through pricing drove sales growth; pricing contributed approximately 22 percentage points, while volume fell about 10 percentage points. The U.S. Amines acquisition contributed approximately 4 percentage points.
- Lower production, primarily due to an extended multi-site third-quarter turnaround and a delayed ramp-up, reduced sales volume. Higher raw-material, utility and turnaround costs largely offset pricing benefits; gross margin was nearly unchanged.
- Ammonium sulfate sales increased to $629 million from $401 million and grew from 24% to 33% of sales. Chemical intermediates declined to $512 million from $545 million and fell from 32% to 26% of sales.
- Operating cash flow increased, aided by working capital, including $31.7 million of customer advances under the ammonium sulfate pre-buy program. Investing cash outflow rose with the U.S. Amines acquisition and higher capital spending.
- AdvanSix acquired U.S. Amines in February 2022 for approximately $97.5 million net of cash acquired, expanding into alkyl and specialty amines. The acquisition added $38.6 million of goodwill; customer-relationship valuation was identified as a critical audit matter.
Outlook, risks and unusual items
- Management expects 2023 capital expenditures of approximately $110–$120 million, focused on reliability, maintenance, safety and environmental projects, capacity and operational improvements.
- Management stated that cash, operating cash flow and available credit are expected to support operating and financing needs. No specific sales or earnings guidance was provided in the supplied filing text.
- Key risks include cyclical markets and weaker end-market demand, commodity and raw-material price volatility, production or logistics interruptions, customer concentration, and environmental, health and safety obligations. The 10 largest customers represented approximately 39% of 2022 sales; Shaw accounted for 12%.
- The company reported an approximately $43 million cumulative unfavorable pre-tax impact since the 2019 Philadelphia Energy Solutions refinery shutdown, which affected a cumene supply source. It had received $4.6 million in insurance proceeds through year-end 2022 and continued pursuing its business-interruption claim.
- EPA and Philadelphia air-management matters involving self-reported emissions-related issues remained under negotiation. Management did not expect either matter to materially affect results or financial position. The company also disclosed ongoing environmental and other litigation contingencies, without estimating reasonably possible losses beyond accruals.
- Dividends paid in 2022 totaled approximately $15.1 million. A quarterly dividend of $0.145 per share was declared in February 2023; the Board retains discretion over future dividends. A further $75 million share-repurchase authorization was announced after year-end.
- The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting. U.S. Amines was excluded from the 2022 internal-control assessment and audit because it was acquired during the year; it represented 4.1% of assets and 3.0% of revenue.
Important facts for investors to verify
- Whether production recovered after the extended 2022 turnaround and how volumes, pricing and margins develop as demand and commodity markets change.
- Whether the U.S. Amines acquisition delivers expected growth and integration benefits; review the assumptions underlying the acquired customer-relationship valuation.
- Whether planned 2023 capital spending and the $115 million of revolver debt affect cash generation, leverage and shareholder returns.
- Progress and potential recovery from the ongoing insurance claim related to the PES shutdown, and the eventual outcomes of the emissions matters and other contingencies.
- How ammonium sulfate customer advances, seasonality and customer concentration affect working capital and cash flow in subsequent periods.